New Migraine Relief: Exploring Gepants for Effective Treatment

Research Summary

In a recent study published in Frontiers in Pharmacology, researchers explored the efficacy of gepants, a new class of CGRP receptor antagonists, for migraine relief. Four gepants—atogepant, ubrogepant, rimegepant, and zavegepant—have been approved, offering alternatives to traditional treatments like triptans. Atogepant is used for prevention, ubrogepant and zavegepant for acute treatment, and rimegepant for both. These medications show promising results, reducing monthly migraine days and achieving high rates of 2-hour pain freedom in trials. They exhibit favorable safety profiles with mild side effects such as nausea and fatigue, presenting a valuable option for those with cardiovascular risks.

Study Details

📄 Title: Gepants: targeting the CGRP pathway for migraine relief.

👥 Research Team: Jakubowska B, Sowa-Kućma M

📚 Published In: Front Pharmacol

📅 Publication Date: 2025

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.